<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507323</url>
  </required_header>
  <id_info>
    <org_study_id>34665: Ticagrelor v Prasugrel</org_study_id>
    <nct_id>NCT02507323</nct_id>
  </id_info>
  <brief_title>Ticagrelor vs. Prasugrel Effects on Infarct Size</brief_title>
  <acronym>TIPRIS</acronym>
  <official_title>TIPRIS: Ticagrelor vs. Prasugrel Effects on Infarct Size: A Head to Head Comparison With Prasugrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yochai Birnbaum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed as a randomized, double-blind trial to provide definitive&#xD;
      evidence on the effects of ticagrelor and prasugrel on myocardial salvage in patients with&#xD;
      anterior ST Segment Elevation Myocardial Infarction (STEMI) undergoing primary Percutaneous&#xD;
      Coronary Intervention (PCI). This study will also measure the effects of ticagrelor vs.&#xD;
      prasugrel on secondary endpoints listed above. This study design aims to test the hypothesis&#xD;
      that ticagrelor will reduce myocardial infarct size as a proportion of the ischemic area at&#xD;
      risk when compared to prasugrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects and research staff (including the Magnetic Resonance Imaging (MRI) readers and&#xD;
      interventional cardiologists) will not know what active treatment study drug the subjects are&#xD;
      receiving.&#xD;
&#xD;
      Study Arm 1: Ticagrelor (180 mg loading dose, followed by 90 mg twice a day) PO plus matching&#xD;
      placebo&#xD;
&#xD;
      Study Arm 2: Prasugrel (60 mg loading dose followed by 5 or 10 mg once per day based on&#xD;
      weight) PO plus matching placebo&#xD;
&#xD;
      Additional study drug: Aspirin (81mg per day)&#xD;
&#xD;
      Participation in this study will be about 90 days and includes 4 study visits (other than&#xD;
      your hospital stay) and 3 telephone calls.&#xD;
&#xD;
      ENROLLMENT PROCEDURES:&#xD;
&#xD;
      The following procedures are to be completed after informed consent has been obtained:&#xD;
&#xD;
        -  Informed Consent Form signed&#xD;
&#xD;
        -  Medical history&#xD;
&#xD;
        -  Vital signs (eg, blood pressure, heart rate, respiration rate, temperature)&#xD;
&#xD;
        -  Review for Adverse Events (AEs) and Serious Adverse Events (SAEs) (only AEs possibly&#xD;
           related to study procedures and SAEs are collected)&#xD;
&#xD;
        -  Documentation of concomitant medications&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Body height&#xD;
&#xD;
        -  Body weight&#xD;
&#xD;
        -  12-lead Electrocardiogram (ECG)&#xD;
&#xD;
        -  Angiographic and Percutaneous Coronary Intervention (PCI) data&#xD;
&#xD;
        -  Randomization of treatment assignment&#xD;
&#xD;
        -  Investigational product dispensing (on Day 0 and during hospital stay) - Loading dose on&#xD;
           Day 0 - 3 day investigational product dosing while in the hospital - 30 day supply&#xD;
           dispensing of investigational product on Day 3 for subject to take home&#xD;
&#xD;
        -  Local laboratory Assessments: - Blood draw for Creatine Kinase-MB (CK-MB) and troponin I&#xD;
           - Blood pregnancy (females of childbearing potential only)&#xD;
&#xD;
      FOLLOW UP PROCEDURES:&#xD;
&#xD;
      Day 5&#xD;
&#xD;
        -  Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature)&#xD;
&#xD;
        -  Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study&#xD;
           procedures and SAEs are collected)&#xD;
&#xD;
        -  Cardiac MRI&#xD;
&#xD;
        -  Left Ventricular Ejection Fraction (LVEF), Left Ventricular End-Diastolic Volume&#xD;
           (LVEDV), Left Ventricular End-Systolic Volume (LVESV) calculations&#xD;
&#xD;
        -  Serum creatinine, Complete Blood Count (CBC)&#xD;
&#xD;
        -  Documentation of concomitant medications and investigational product compliance&#xD;
&#xD;
      Day 30 (+/- 1 day), Day 60 (+/- 2 days)&#xD;
&#xD;
        -  Vital signs (e.g., blood pressure, heart rate, respiration rate, temperature)&#xD;
&#xD;
        -  Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study&#xD;
           procedures and SAEs are collected)&#xD;
&#xD;
        -  LVEF, LVEDV, LVESV calculations&#xD;
&#xD;
        -  Serum creatinine, CBC&#xD;
&#xD;
        -  Documentation of concomitant medications and investigational product compliance&#xD;
&#xD;
        -  Investigational Product Dispensing&#xD;
&#xD;
      Day 14, Day 44, Day 74 (+/- 2 days):&#xD;
&#xD;
      Phone calls will be performed to ensure drug compliance, review concomitant medications and&#xD;
      review any events. On Day 74, study staff will confirm whether or not the subject has seen&#xD;
      their regular cardiologist. Subject will be instructed to bring this information with them at&#xD;
      the Day 90 visit so that their cardiologist can be told what arm they participated in for&#xD;
      continuation of care and medication therapy.&#xD;
&#xD;
      Day 90 or Termination/End of Study (+/- 2 days) :&#xD;
&#xD;
        -  Vital signs (eg, sitting blood pressure, heart rate, respiration rate, temperature)&#xD;
&#xD;
        -  Review for Adverse Events and Serious Adverse Events (only AEs possibly related to study&#xD;
           procedures and SAEs are collected)&#xD;
&#xD;
        -  Cardiac MRI&#xD;
&#xD;
        -  LVEF, LVEDV, LVESV calculations&#xD;
&#xD;
        -  Serum creatinine, CBC&#xD;
&#xD;
        -  Documentation of concomitant medications and investigational product compliance&#xD;
&#xD;
        -  If available and subject consents, subject's cardiologist will be informed what arm of&#xD;
           the study they participated in for continuation of care and medication therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    collaborator withdrew the study&#xD;
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by infarct size on all randomized patients.</measure>
    <time_frame>up to Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by incidences of treatment emergent adverse events, serious adverse events, treatment-related adverse events and adverse events leading to stop of drug</measure>
    <time_frame>90 days</time_frame>
    <description>for 90 day major adverse cardiac events and bleeding complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ticagrelor or matching placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prasugrel or matching placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>A platelet aggregation inhibitor</description>
    <arm_group_label>ticagrelor or matching placebo</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>a thienopyridine class inhibitor of platelet activation and aggregation</description>
    <arm_group_label>prasugrel or matching placebo</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>prasugrel or matching placebo</arm_group_label>
    <arm_group_label>ticagrelor or matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent: Signed informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Age: Male and females aged 18 years and older&#xD;
&#xD;
          3. Onset: Presenting to emergency room or cardiac catheterization laboratory within 6&#xD;
             hours of onset of myocardial infarction symptoms&#xD;
&#xD;
          4. Continuing to have ongoing myocardial infarction symptoms&#xD;
&#xD;
          5. EKG findings: ST elevation on ECG with positive T waves in the precordial leads,&#xD;
             suggestive of anterior STEMI&#xD;
&#xD;
          6. Triaged for emergency cardiac catheterization (primary PCI protocol)&#xD;
&#xD;
          7. Agree to use an effective contraceptive method beginning at the signing of the&#xD;
             informed consent and for at least 30 days after the last dose of study drug. The&#xD;
             definition of an effective method of contraception will be based on the judgment of&#xD;
             the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior myocardial infarction&#xD;
&#xD;
          2. Contraindication to ticagrelor and/or prasugrel&#xD;
&#xD;
          3. Contraindication to gadolinium&#xD;
&#xD;
          4. Contraindication to aspirin&#xD;
&#xD;
          5. Treatment with fibrinolytic therapy for the index STEMI&#xD;
&#xD;
          6. High risk of bleeding&#xD;
&#xD;
          7. Presenting with cardiogenic shock&#xD;
&#xD;
          8. Infarction due to stent thrombosis&#xD;
&#xD;
          9. History of a previous coronary artery bypass graft (CABG)&#xD;
&#xD;
         10. Known renal insufficiency (acute kidney injury or Glomerular Filtration Rate &lt; 40&#xD;
             mL/min/1.73 m2).&#xD;
&#xD;
         11. Moderate or severe hepatic impairment&#xD;
&#xD;
         12. Inability to undergo cardiac MRI&#xD;
&#xD;
         13. Indication for aspirin &gt;162 mg/d&#xD;
&#xD;
         14. Indication for Nonsteroidal Anti-Inflammatory Drugs or COX2 inhibitors&#xD;
&#xD;
         15. Pregnant&#xD;
&#xD;
         16. Breast feeding&#xD;
&#xD;
         17. History of intracranial hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yochai Birnbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor-St. Lukes Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Yochai Birnbaum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

